Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 9/20 | 0.36 |
| ▸ | PGR | P06401 | 5/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 2/20 | 0.32 |
| ▸ | CLK3 | P49761 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624349 | 0.80 | DAO (0.49) | NR3C1NR3C2PGRDAOSYK | |
| SCHEMBL23478697 | 0.80 | NR3C1 (0.35) | NR3C1NR3C2PGRDAOSYK | |
| SCHEMBL21942066 | 0.75 | DAO (0.44) | NR3C1NR3C2PGRDAOMAPT | |
| SCHEMBL20993310 | 0.75 | NR3C1 (0.38) | NR3C1NR3C2PGRDAOMAPT | |
| SCHEMBL23452979 | 0.72 | DAO (0.42) | NR3C1NR3C2PGRDAOMAPT | |
| SCHEMBL12571647 | 0.68 | DAO (0.49) | NR3C1NR3C2PGRDAOSYK | |
| SCHEMBL27452061 | 0.68 | CYP2A6 (0.36) | NR3C1NR3C2PGRSYKMAPT | |
| SCHEMBL22025096 | 0.66 | RIPK1 (0.39) | NR3C1NR3C2DAOSYKCLK2 | |
| SCHEMBL19663767 | 0.65 | ALDH1A1 (0.35) | SYKMAPT | |
| SCHEMBL26262624 | 0.65 | CYP1A2 (0.38) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NR3C1 4645/4885NR3C2 2658/4885PGR 4682/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | NR3C1 4645/4885NR3C2 2658/4885PGR 4682/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NR3C1 4645/4885NR3C2 2658/4885PGR 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.